Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States

por Chatterjee, Anuja, Shapouri, Sheila, Manzoor, Beenish S, Ravelo, Arliene, Sail, Kavita, Qendri, Venetia, van de Wetering, Gijs, Davids, Matthew S
Publicado 2021

A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada

por Chatterjee, Anuja, van de Wetering, Gijs, Goeree, Ron, Owen, Carolyn, Desbois, Anne Marie, Barakat, Stephane, Manzoor, Beenish S., Sail, Kavita
Publicado 2022

P647: RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL

por Rhodes, Joanna, Shadman, Mazyar, Lamanna, Nicole, S. Manzoor, Beenish, Coombs, Catherine, Ghosh, Nilanjan, H. Tuncer, Hande, Emechebe, Dozie, R. Brown, Jennifer, Alhasani, Hasan, Leslie, Lori, Roeker, Lindsey, Ujjani, Chaitra, Eichhorst, Barbara, Fleury, Isabelle, Skarbnik, Alan, T. Hill, Brian, Lansigan, Frederick, M. Barr, Paul, Davids, Matthew, Fox, Christopher, Choi, Yun, E. Jensen, Christopher, Schuh, Anna, Kennard, Kaitlin, Jawaid, Dureshahwar, Pivneva, Irina, Watson, Talissa, Eyre, Toby
Publicado 2023

P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY

por Lansigan, Frederick, A. Eyre, Toby, Ghosh, Nilanjan, S. Manzoor, Beenish, C. Coombs, Catherine, Lamanna, Nicole, H. Tuncer, Hande, Emechebe, Dozie, R. Brown, Jennifer, E. Roeker, Lindsey, Ujjani, Chaitra, Alhasani, Hasan, Fleury, Isabelle, A. Leslie, Lori, Skarbnik, Alan, Rhodes, Joanna, T. Hill, Brian, M. Barr, Paul, S. Davids, Matthew, P. Fox, Christopher, Choi, Yun, Schuh, Anna, Kennard, Kaitlin, E. Jensen, Christopher, Jawaid, Dureshahwar, Sharma, Aditya, Pivneva, Irina, Watson, Talissa, Shadman, Mazyar
Publicado 2023

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

por Thompson, Meghan C., Harrup, Rosemary A., Coombs, Catherine C., Roeker, Lindsey E., Pu, Jeffrey J., Choi, Michael Y., Barr, Paul M., Allan, John N., Šimkovič, Martin, Leslie, Lori, Rhodes, Joanna, Chong, Elise A., Kamdar, Manali, Skarbnik, Alan, Lansigan, Frederick, McCall, Brittany, Saja, Khalid, Dyer, Martin J.S., Walter, Harriet S., Lefebure, Marcus, Thadani-Mulero, Maria, Boyer, Michelle, Biondo, Juliana, Sail, Kavita, Manzoor, Beenish S., Furman, Richard, Bantilan, Kurt S., Goy, Andre, Feldman, Tatyana, Labella, Dominic, Schuster, Stephen J., Park, Jae, Palomba, Lia, Zelenetz, Andrew, Eyre, Toby A., Kater, Arnon P., Seymour, John F., Mato, Anthony R.
Publicado 2022